Primary exudative lymphoma (PEL) is a lymphoma that often expresses CD38, but despite high CD38 expression, daratumumab does not induce complement-dependent cytotoxicity (CDC) in PEL but increases antibody-dependent cell-mediated cellular cytotoxicity (ADCC), and ATRA and pomalidomide significantly increase the CD38 levels in low CD38-expressing PEL cell lines, which in turn increases daratumumab-induced ADCC, and daratumumab in combination with ATRA or pomalidomide is a potential therapeutic option for PEL (Shrestha et al., 2023). Here, CD38 is linked to primary effusion lymphoma.